7 uger) og den samlede overlevelse signifikant længere for docetaxel ved doseringen 75 mg/ m2 end for bedste palliative behandling.
In a phase III study, in previously treated patients, time to progression (12.3 weeks versus 7 weeks) and overall survival were significantly longer for docetaxel at 75 mg/ m² compared to Best Supportive Care.